Wolverine Trading’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$3.11M Sell
25,100
-3,600
-13% -$439K ﹤0.01% 1784
2025
Q2
$3.44M Sell
28,700
-10,600
-27% -$1.19M ﹤0.01% 1308
2025
Q1
$4.42M Buy
39,300
+24,600
+167% +$2.62M 0.01% 1056
2024
Q4
$1.43M Sell
14,700
-500
-3% -$53.3K ﹤0.01% 2299
2024
Q3
$1.76M Buy
+15,200
New +$1.72M ﹤0.01% 1809
2024
Q2
Sell
-18,300
Closed -$1.77M 5006
2024
Q1
$1.77M Buy
18,300
+12,400
+210% +$1.27M ﹤0.01% 1699
2023
Q4
$596K Sell
5,900
-24,500
-81% -$2.36M ﹤0.01% 2770
2023
Q3
$3.1M Buy
30,400
+12,100
+66% +$1.23M ﹤0.01% 1296
2023
Q2
$1.82M Buy
18,300
+2,000
+12% +$200K ﹤0.01% 1534
2023
Q1
$1.49M Buy
+16,300
New +$1.42M ﹤0.01% 1583
2022
Q3
Sell
-12,700
Closed -$1.08M 5103
2022
Q2
$1.08M Sell
12,700
-800
-6% -$70.2K ﹤0.01% 1853
2022
Q1
$1.19M Sell
13,500
-34,200
-72% -$2.96M ﹤0.01% 2274
2021
Q4
$4.17M Buy
47,700
+15,200
+47% +$1.26M ﹤0.01% 1269
2021
Q3
$2.69M Buy
+32,500
New +$2.92M ﹤0.01% 1829
2021
Q2
Sell
-43,400
Closed -$3.78M 6486
2021
Q1
$3.78M Buy
+43,400
New +$3.89M 0.01% 1351
2020
Q3
Sell
-49,400
Closed -$4.31M 4953
2020
Q2
$4.31M Sell
49,400
-8,600
-15% -$742K 0.01% 893
2020
Q1
$4.75M Sell
58,000
-8,400
-13% -$749K 0.01% 794
2019
Q4
$6.28M Buy
66,400
+26,800
+68% +$2.4M 0.02% 937
2019
Q3
$3.46M Sell
39,600
-14,000
-26% -$1.26M 0.01% 1077
2019
Q2
$4.89M Sell
53,600
-18,270
-25% -$1.55M 0.01% 892
2019
Q1
$6.19M Buy
71,870
+5,580
+8% +$448K 0.02% 755
2018
Q4
$5.06M Buy
66,290
+23,770
+56% +$1.85M 0.01% 803
2018
Q3
$3.28M Buy
+42,520
New +$3.14M 0.01% 1258
2018
Q1
Sell
-47,988
Closed -$3.61M 5614
2017
Q4
$3.61M Buy
+47,988
New +$3.62M 0.01% 1078
2017
Q1
Sell
-47,318
Closed -$3.09M 4772
2016
Q4
$3.09M Buy
47,318
+12,945
+38% +$840K 0.02% 1048
2016
Q3
$2.44M Buy
34,373
+20,200
+143% +$1.47M 0.01% 1194
2016
Q2
$1.03M Buy
+14,173
New +$979K 0.01% 1569

Other funds holding NVS

Wolverine Trading's NVS Position: Q3 2025 in Review

Wolverine Trading reduced its Novartis (NVS) stake by 53% in Q3 2025, selling an estimated $618K and leaving 4,415 shares worth $548K. The position accounts for ﹤0.01% of the portfolio, ranked #3607.

Wolverine Trading first reported a position in NVS in Q2 2016 and has held it in 21 quarters since. The position peaked at $5M in Q2 2019. 1,400 funds tracked by Wall St. Rank hold NVS as of Q3 2025.

  • Wolverine Trading held 4,415 shares of Novartis worth $548K as of Q3 2025.
  • Wolverine Trading sold 5,061 Novartis shares in Q3 2025, an estimated $618K.
  • Novartis made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #3607 holding.
  • Wolverine Trading first reported a position in Novartis in Q2 2016 and has held it in 21 quarters since.
  • Wolverine Trading's Novartis position peaked at $5M in Q2 2019.
  • 1,400 funds tracked by Wall St. Rank held Novartis as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.